Skip to content

Vitamin D Supplementation in Wheelchair Indoor Athletes

Effect of Vitamin D3 Supplementation on Exercise Performance in Wheelchair Athletes.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02621320
Acronym
VitD_SCI
Enrollment
20
Registered
2015-12-03
Start date
2015-11-30
Completion date
2016-08-31
Last updated
2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Supplements, Drug Effects, Physical Education and Training/Methods, Spinal Cord Injury, Vitamin D Deficiency

Keywords

Vitamin D, Exercise Performance, Wheelchair Athletes, Indoor sports, Wingate, Isokinetic Dynamometer

Brief summary

There is a high prevalence of vitamin D deficiency in Switzerland. In indoor-athletes as well as wheelchair users, vitamin D deficiency occurs even more often. It is well established that vitamin D deficiency has a negative effect on health. However, vitamin D supplementation in individuals with a vitamin D deficiency has a positive effect on muscle performance. In recently published studies with able-bodied subjects, it has been shown that a normal vitamin D level (\>75nmol/L) can only be achieved with a high-dose supplementation of vitamin D. The aim of this study is to examine the effect of vitamin D supplementation on exercise performance in wheelchair athletes with vitamin D deficiency . All participants with a vitamin D deficiency are assigned to the intervention group and treated with 6000 IU of vitamin D3 daily over a period of 12 weeks. All participants who have a normal vitamin D level will receive placebo treatment (control group). The physical performance is measured three times at baseline, after six weeks and 12 weeks. The measurements include a Wingate and a dynamometer test.

Interventions

DIETARY_SUPPLEMENTVitamin D

Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.

DIETARY_SUPPLEMENTPlacebo

alcohol-based solution 1.3ml daily over a period of 12 weeks.

Sponsors

Swiss Paraplegic Research, Nottwil
Lead SponsorNETWORK

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* swiss elite wheelchair athlete * 18 to 60 years * male, healthy * at least 2x45min sports a week

Exclusion criteria

* participation in another study * medication which influences performance * respiratory and cardiovascular disease * daily intake of \>400IU Vitamin D * parathyroid gland disease * kidney insufficiency * visit abroad below the 37th parallel latitude during study or shortly before

Design outcomes

Primary

MeasureTime frameDescription
peak powerdelta change from pre to 12 weeks post supplementationpeak power measured during wingate test
maximum torquedelta change from pre to 12 weeks post supplementationmaximum torque measured with dynamometer

Secondary

MeasureTime frameDescription
Vitamin D serum levelweek 0, 1 day before they start supplementationmeasured with venous blood sample
Count of injuries12 weeks post supplementationDASH questionaire

Other

MeasureTime frameDescription
Heart rateweek 0, 1 day before they start supplementationPeak heart rate measured during wingate test
blood lactate concentrationweek 0, 1 day before they start supplementationbefore, during and after wingate test

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026